▸ 12 Oct 2026, 16:23 Annual Report to Shareholders Financial Results
▸ 12 Oct 2026, 16:13 Notice of Annual General Meeting and Proxy Form Meetings & Governance
▸ 12 Oct 2026, 16:05 Appendix 4G and Corporate Governance Statement Company Administration
▸ 1 Oct 2026, 18:49 Ceasing to be a substantial holder Substantial Holders
▸ 30 Sep 2026, 18:15 Becoming a substantial holder Substantial Holders
▸ 24 Sep 2026, 09:52 FDA Approves New Potency Assay for Commercial Ryoncil Company Update
▸ 23 Sep 2026, 18:41 Ceasing to be a substantial holder Substantial Holders
▸ 27 Aug 2026, 08:39 MSB Annual Financial Results and Operational Update Financial Results
▸ 27 Aug 2026, 08:33 Annual Financial Results Presentation Financial Results
▸ 27 Aug 2026, 08:21 Preliminary Final Report including Appendix 4E Financial Results
▸ 24 Aug 2026, 17:50 Appendix 3Y - Philip Krause Director Interests
▸ 24 Aug 2026, 17:40 Notification regarding unquoted securities - MSB Securities Administration
▸ 24 Aug 2026, 17:38 Mesoblast 2026 Full Year Financial Results Webcast Presentations
▸ 17 Aug 2026, 10:00 Major Milestone Treatment Completed in P3 Trial for CLBP Company Update
▸ 13 Aug 2026, 17:52 Becoming a substantial holder Substantial Holders
▸ 7 Aug 2026, 17:02 Ceasing to be a substantial holder Substantial Holders
▸ 5 Aug 2026, 18:29 Becoming a substantial holder Substantial Holders
▸ 3 Aug 2026, 17:25 Ceasing to be a substantial holder Substantial Holders
▸ 31 Jul 2026, 17:06 Becoming a substantial holder Substantial Holders
▸ 30 Jul 2026, 10:01 Quarterly Activities/Appendix 4C Cash Flow Report Quarterly Reports
▸ 24 Jul 2026, 17:00 Ceasing to be a substantial holder Substantial Holders
▸ 22 Jul 2026, 08:23 Ceasing to be a substantial holder Substantial Holders
▸ 21 Jul 2026, 09:53 Mesoblast CEO Makes Investment to Increase Share Ownership Substantial Holders
▸ 21 Jul 2026, 09:47 Appendix 3Y - Silviu Itescu Director Interests
▸ 21 Jul 2026, 09:43 Notification regarding unquoted securities - MSB Securities Administration
▸ 21 Jul 2026, 09:33 Application for quotation of securities - MSB Securities Administration
▸ 14 Jul 2026, 17:31 Notification of cessation of securities - MSB Securities Administration
▸ 14 Jul 2026, 17:25 Notification regarding unquoted securities - MSB Securities Administration
▸ 14 Jul 2026, 17:21 Application for quotation of securities - MSB Securities Administration
▸ 14 Jul 2026, 17:15 Notification regarding unquoted securities - MSB Securities Administration
▸ 14 Jul 2026, 17:12 Appendix 3Y - Silviu Itescu Director Interests
▸ 14 Jul 2026, 10:00 Pivotal Phase 3 Trial in CLBP Achieves 300 Treated Patients Company Update
▸ 10 Jul 2026, 09:57 Ryoncil Q4 Net Revenue of US$36M and US$115M for Full Year Periodic Reports
▸ 1 Jul 2026, 09:56 Receives FDA BLA Filing Number and Requests Modular Review Company Update
▸ 30 Jun 2026, 08:13 Becoming a substantial holder Substantial Holders
▸ 29 Jun 2026, 08:18 Ceasing to be a substantial holder Substantial Holders
▸ 25 Jun 2026, 09:55 Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility Capital Raising
▸ 16 Jun 2026, 08:18 Becoming a substantial holder Substantial Holders
▸ 12 Jun 2026, 08:23 Ceasing to be a substantial holder Substantial Holders
▸ 2 Jun 2026, 11:51 ASX CEO Connect Presentation Presentations
▸ 30 Apr 2026, 09:56 Quarterly Activities/Appendix 4C Cash Flow Report Quarterly Reports
▸ 29 Apr 2026, 09:50 Patient Recruitment Target Achieved in CLBP Pivotal Trial Company Update
▸ 16 Apr 2026, 17:22 Appendix 3Y for Gregory George Director Interests
▸ 16 Apr 2026, 17:13 Notification of cessation of securities - MSB Securities Administration
▸ 16 Apr 2026, 17:09 Notification regarding unquoted securities - MSB Securities Administration
▸ 16 Apr 2026, 17:05 Application for quotation of securities - MSB Securities Administration
▸ 16 Apr 2026, 17:03 Notification regarding unquoted securities - MSB Securities Administration
▸ 15 Apr 2026, 09:25 Acquires CAR Platform for Precision-Enhanced Cell Products Mergers & Acquisitions
▸ 8 Apr 2026, 19:16 Mesoblast R&D Day Presentation Presentations
▸ 8 Apr 2026, 19:08 Mesoblast R&D Day Features Commercial & Blockbuster Programs Presentations
▸ 8 Apr 2026, 12:31 FDA Clears Ryoncil IND for Registration Trial in DMD Company Update
▸ 8 Apr 2026, 10:00 Application for quotation of securities - MSB Securities Administration
▸ 8 Apr 2026, 09:54 Cleansing Notice Securities Administration
▸ 7 Apr 2026, 17:19 Proposed issue of securities - MSB Securities Administration
▸ 7 Apr 2026, 10:12 Ryoncil Net Revenue for the Quarter Increases to US$30.3M Company Update
▸ 20 Mar 2026, 17:23 Appendix 3Ys - S Itescu, E Rose, G George and L Cobley Director Interests
▸ 20 Mar 2026, 16:51 Notification regarding unquoted securities - MSB Securities Administration
▸ 18 Mar 2026, 09:54 Mesoblast to Host R&D Day on April 8, 2026 Presentations
▸ 12 Mar 2026, 17:05 Replacement Appendix 3Y for Gregory George Director Interests
▸ 12 Mar 2026, 09:58 Appointment of Clinical Development and Medical Affairs Head Company Administration
▸ 10 Mar 2026, 15:28 Becoming a substantial holder Substantial Holders
▸ 10 Mar 2026, 09:39 Appendix 3Y for Gregory George Director Interests
▸ 9 Mar 2026, 11:33 Change in substantial holding Substantial Holders
▸ 27 Feb 2026, 09:02 Ryoncil Profits Underpinning Substantial Growth Pipeline Financial Results
▸ 27 Feb 2026, 08:49 Corporate Presentation and Half Year Financial Results Financial Results
▸ 27 Feb 2026, 08:42 Half Year Report and Accounts (including Appendix 4D) Financial Results
▸ 20 Feb 2026, 16:53 Mesoblast 2026 Half Year Financial Results Webcast Presentations
▸ 12 Feb 2026, 10:02 High Survival Rates with Ryoncil in SR-aGvHD EIND Program Company Update
▸ 9 Feb 2026, 08:11 Becoming a substantial holder Substantial Holders
▸ 29 Jan 2026, 10:05 Quarterly Activities/Appendix 4C Cash Flow Report Quarterly Reports
▸ 27 Jan 2026, 10:20 Real World Experience with Ryoncil Shows 84% Early Survival Company Update
▸ 27 Jan 2026, 08:25 Ceasing to be a substantial holder Substantial Holders
▸ 27 Jan 2026, 08:10 Becoming a substantial holder Substantial Holders
▸ 19 Jan 2026, 10:04 FDA Confirms Path to Approval for CLBP Company Update
▸ 15 Jan 2026, 17:53 Notification of cessation of securities - MSB Securities Administration
▸ 15 Jan 2026, 17:49 Notification regarding unquoted securities - MSB Securities Administration
▸ 13 Jan 2026, 19:15 Notification regarding unquoted securities - MSB Securities Administration
▸ 13 Jan 2026, 19:06 Application for quotation of securities - MSB Securities Administration
▸ 13 Jan 2026, 18:58 Appendix 3Y for Eric Rose Director Interests
▸ 12 Jan 2026, 09:52 Appendix 3Y for Lyn Cobley Director Interests
▸ 9 Jan 2026, 09:57 Ryoncil Sales for the Quarter Increase 60% to US$35.1M Periodic Reports
▸ 6 Jan 2026, 18:31 Appendix 3Y for Gregory George Director Interests
▸ 6 Jan 2026, 18:18 Notification of cessation of securities - MSB Securities Administration
▸ 2 Jan 2026, 09:38 Mesoblast Announces Changes to Board of Director Roles Company Administration
▸ 30 Dec 2025, 16:19 Release of Shares from Voluntary Escrow Securities Administration
▸ 30 Dec 2025, 10:21 Proposed issue of securities - MSB Securities Administration
▸ 30 Dec 2025, 10:02 Mesoblast Enters into Non-Dilutive Lower Cost 5-Year Credit Capital Raising
▸ 23 Dec 2025, 17:30 Appendix 3Y for Gregory George Director Interests
▸ 19 Dec 2025, 08:17 Ceasing to be a substantial holder Substantial Holders
▸ 17 Dec 2025, 18:47 Notification regarding unquoted securities - MSB Securities Administration
▸ 17 Dec 2025, 08:22 Becoming a substantial holder Substantial Holders
▸ 16 Dec 2025, 19:52 Warrant Prospectus Related to Convertible Note Agreements Securities Administration
▸ 12 Dec 2025, 10:02 Study at ASH Concludes Remestemcel-L Superiority in SR-aGvHD Company Update
▸ 10 Dec 2025, 20:17 Ceasing to be a substantial holder Substantial Holders
▸ 9 Dec 2025, 17:57 Becoming a substantial holder Substantial Holders
▸ 4 Dec 2025, 09:52 Mesoblast Participation at Piper Sandler Conference Company Administration
▸ 27 Nov 2025, 18:32 Ceasing to be a substantial holder Substantial Holders
▸ 25 Nov 2025, 14:32 Results of Meeting Meetings & Governance
▸ 25 Nov 2025, 10:00 Ryoncil Revenue Growth Highlighted in AGM Trading Update Periodic Reports
▸ 25 Nov 2025, 09:52 CEO Presentation to 2025 Annual General Meeting Presentations